YAP1 and Miyoshi myopathy: More precise and rapid assays, along with more effective MM biomarkers, are needed to accurately determine which MM cases are associated with activated YAP1/TAZ (e.g., for drug development or patient screening) in the context of both laboratory and clinical trial-based research.